The researchers, at Johannes Gotenberg University, simultaneously investigated the serum activities of DR-70 and the standard test, CA-125, in 61 preoperative patients with histologically confirmed ovarian carcinoma, and one hundred healthy people.
In the test, DR-70 was shown to be 100% effective in detecting the presence of cancer and 83.6% effective in determining the type of cancer – 13.1% higher than the standard test.
The German researchers concluded that “DR-70 represents a tumor marker with which ovarian carcinoma can be diagnosed at levels of sensitivity and specificity which compare favorably to those measured with CA-125.” The study is published in the German Journal of Obstetrics and Gynecology.
Gary Dreher, AMDL CEO emphasized that the company’s primary objective remains receiving FDA clearance to market DR-70, which would simultaneously increase market awareness and acceptance in the international marketplace.